



#### STATE OF TENNESSEE

## DEPARTMENT OF FINANCE AND ADMINISTRATION

DIVISION OF MENTAL RETARDATION SERVICES ANDREW JACKSON BUILDING 500 DEADERICK STREET, 15<sup>TH</sup> FLOOR NASHVILLE, TENNESSEE 37243

### MEMORANDUM

TO: DMRS Regional Directors, Agency Directors, DMRS Regional Training Coordinators,

Agency Trainers, DMRS Regional Investigators, DMRS Regional Incident Management Coordinators, Agency Incident Management Coordinators, DMRS Regional Nurse

Educators, Therapy Providers

FROM: Stephen H. Norris

Deputy Commissioner

DATE: October 11, 2006

RE: Medication Variance Reporting

The Division of Mental Retardation Services (DMRS) has revised the medication error reporting form entitled Medication Variance MR0484 7-06. The change to the form now reflects if a person administering medications is not certified. This box is located in Section 3 titled, Practitioner/Staff Involved. This item is marked with an asterisk (\*) and a footnote is included. A selection in this item will require that a copy of the variance form be submitted to the DMRS Investigator with the Reportable Incident Form. Submission of the Medication Variance report noting the administration of medications by non-certified staff does not automatically warrant an investigation. This will be determined once the information is received and reviewed by the DMRS Investigations unit.

Regional Nurse Educators will send notification of this change to all trainers for this course as well as trainers of the Medication Administration for Unlicensed Personnel course immediately. The revised form (7-06) will be used by trainers as soon as they are notified.

Each agency will be responsible for notifying previously trained staff of this additional requirement and use of the DMRS approved medication variance form in accordance with Provider Manual Chapter 11, 11.8.a.

2). Trending of medication variance concerns should include the category of not certified staff.

Should you have questions please contact the Regional Nurse Educator: East-Joyce Couch, RN (423-798-6255); Middle-Bill Feldhaus, RN (615-231-5432); West-Rosie Key, RN (901-741-7814) or Ruth Givens, DMRS Nurse Education Coordinator (615-532-6547).

### SHN/rs

copy: Pat Nichols, DMRS Director of Quality Assurance

John Kaufman, DMRS Director of Compliance

Adadot Hayes MD, DMRS Medical Director

**DMRS Nursing Services** 

Karen Wills, Director of Therapeutic Services

Debbie Payne, DMRS Director of Protection from Harm Doug Burroughs, DMRS Director of Incident Management

Carol Wilkin, DMRS Director of Investigations

Kim Dean, DMRS Director of Training

Diana Davis, DMRS Compliance Coordinator

# **DMRS Medication Variance Report**

Section 1: Name	Section 2. Benedician eniConff Investment
Age	Section 3: Practitioner/Staff Involved Classification Status
SS /Case #	() Nurse () Regular
	() Pharmacist () Agency/Contract
	() Physician () Float
Section 2: Time & Location of Variance (circle)	( ) Direct Support Staff ( ) Other
Day of the Week: Su Mo Tu We Th Fr Sa	() Respiratory Therapist () Not certified to check here
Date/Time of event;(circle AM/PM)	( ) Other requires investigator notification)
Location	( ) 4 mm
Agency	
Physician NotifiedDate/Time	Duration of variancedayshours
Section 4: Medication and Doses Involved  Drug <u>ordered</u> and route  Drug <u>given</u> and route	Section 5: What hannened? (Check all that apply)  INCORRECT () Person () Given when criteria (e.g.
	() Drug BP, blood sugar, pain)
Route: Route:	() Dose not met
() IV push	17 _
() IV drip () IV drip	.,
() IM () IM	( ) Formulation more than scheduled doses ( ) IV Rate or given after step
() SC () SC	
() PO () PO	() IV Solution date or after discontinued)
11	() Time () Given in the presence of
() ( )	( ) Position documented allergy to
<u> </u>	() Texture drug
() Per trach () Per trach	( ) Dose Omitted ( ) Treatment Error
() Topical	( ) Other
() Vaginal () Vaginal	
( ) Other	Form of variance: () actual () potential
) DISPENSING: (e.g. medication mistabeled, wrong medication stocked in attelline p  ) ADMINISTERING: (e.g. medication label misread or not read, previous dose git	ns, lack of safe drug storage and stocking practices, lack of standardization of stock drug concentrations, exp charmacy, wrong medication withdrawn from satellite pharmacy, inaccurate dose calculation, etc) was but not charted or charted incorrectly, person identification not verified, person not available on unit, exc a or procedures not ordered, test procedure results misinterpreted, test procedure results not charted or chart
<ul> <li>PRODUCT (e.g., unclear manufacturing labeling, "sound-alike" dn such as "fos" phenytoin or diltiazem "CD" etc.)</li> <li>MEDICATION USE SYSTEM (e.g. side-by-side storage of look-</li> </ul>	e there factors that made this variance difficult to prevent or detect?  ug names, look-alike packaging, omission or misuse of a prefix or suffix  alike drugs, lack of standardization in practice, competing distractions, etc.)  ud timely written and oral communications related to drug regimen, lack of  abarrassment etc.)
Classification II () Category B: Variance occurred, but was detection II () Category C: Variance occurred, reached the Classification II () Category D: Variance will require additionate	ave the capacity to cause a medication-use variance ected before it reached the individual individual, but caused no harm or is unlikely to cause harm I person monitoring, but is unlikely to result in a change in vital signs or cause hand caused or is likely to cause the person temporary harm requiring hospitalization cause temporary harm to the person the person temporary harm to the person the person the person it (e.g. anaphylaxis, cardiac arrest) ited to the person's death
ection 9: Your comments. In your opinion, are there improvements or charges that	the completion of a Reportable Incident form. (In addition to Ints form)  can be made to belp prevent a similar event from occurring again? Intervention (e.g. training, monitoring.
Section 9: Your comments. In your opinion, are there improvements or changes that orrection made to MAR, medication obtained, etc.).	the Completion of the Reportable Incident Jorna, (In addition to Int. Jorna)  can be made to help prevent a similar event from occurring again? Intervention (e.g. training, monitoring,
ection 9: Your comments. In your opinion, are there improvements or charges the	the Compension of a Reportable Incident Jorna, (In Addition to Init Jorna)  can be made to bely preven a similar event from occurring again? Intervention (e.g. training, monitoring,

MR-0484 Revised 7-06

A copy of the Veriance form must be submitted with the Reportable Incident Form\*\*
 A copy of the Veriance form must be submitted to the Investigator with the Reportable Incident Form.